Candel Therapeutics adds Martine Zimmermann to board ahead of planned BLA filing
The regulatory and quality veteran joins as Candel prepares a fourth-quarter 2026 BLA submission for aglatimagene besadenovec.
SEC filing
Latest
2 stories
Thursday, September 10
Thursday, August 13
Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trial
Candel reported second-quarter 2026 results with $201.6 million in cash, said to fund operations into the first quarter of 2028, alongside progress on its lead program.
SEC filing